Frontiers in pediatrics · 2025
Endoscopic ultrasound safety and efficacy in pediatric pancreatobiliary and gastrointestinal disorders: single-center retrospective trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Jiayu, Deng Zhaohui
Аннотация
BACKGROUND: While endoscopic ultrasound (EUS) is well established as a standard diagnostic and therapeutic tool in adults, its use in children remains limited. This study assessed the indications, safety, and clinical impact of diagnostic and therapeutic EUS in children with pancreatobiliary and gastrointestinal disorders.
METHODS: We retrospectively analyzed pediatric patients with pancreatobiliary and gastrointestinal disorders who underwent EUS at our institution between January 2022 and June 2025.
RESULTS: Fifty-three EUS procedures were conducted in children with a median age of 9.6 ± 3.0 years. Indications for EUS included acute recurrent pancreatitis (n = 15), suspected chronic pancreatitis (n = 12), suspected choledocholithiasis (n = 7), obstructive jaundice (n = 5), pancreatic mass (n = 1), gastric mucosal lesions (n = 6), suspected esophageal lymphoma recurrence (n = 1), suspected autoimmune hepatitis (n = 1) and pancreatic pseudocyst (PPC, n = 5). ERCP was performed during the same anesthesia for all children requiring it post-EUS. Five patients underwent cystogastrostomy for symptomatic PPC with 100% technical and clinical success. The efficacy of EUS in guiding definitive therapeutic decisions and invasive interventions was 100%. Notably, no major complications occurred.
CONCLUSION: EUS is safe and effective diagnostic and therapeutic modality in pediatric patients with pancreatobiliary and gastrointestinal disorders.
METHODS: We retrospectively analyzed pediatric patients with pancreatobiliary and gastrointestinal disorders who underwent EUS at our institution between January 2022 and June 2025.
RESULTS: Fifty-three EUS procedures were conducted in children with a median age of 9.6 ± 3.0 years. Indications for EUS included acute recurrent pancreatitis (n = 15), suspected chronic pancreatitis (n = 12), suspected choledocholithiasis (n = 7), obstructive jaundice (n = 5), pancreatic mass (n = 1), gastric mucosal lesions (n = 6), suspected esophageal lymphoma recurrence (n = 1), suspected autoimmune hepatitis (n = 1) and pancreatic pseudocyst (PPC, n = 5). ERCP was performed during the same anesthesia for all children requiring it post-EUS. Five patients underwent cystogastrostomy for symptomatic PPC with 100% technical and clinical success. The efficacy of EUS in guiding definitive therapeutic decisions and invasive interventions was 100%. Notably, no major complications occurred.
CONCLUSION: EUS is safe and effective diagnostic and therapeutic modality in pediatric patients with pancreatobiliary and gastrointestinal disorders.